(EMAILWIRE.COM, April 25, 2017 ) Browse 105 market data Tables and 45 Figures spread through 162 Pages and in-depth TOC on "Genome Editing/Genome Engineering Market"
http://www.marketsandmarkets.com/Market-Reports/genome-editing-engineering-market-231037000.html
Early buyers will receive 10% customization on this report.

The global genome editing market is segmented on the basis of technology, application, end user and region.

By technology, the genome editing market is categorized into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, and Jump-In). In 2016, the CRISPR segment is expected to command the largest share of the global genome editing market. The CRISPR segment is also expected to grow at the highest CAGR from 2016 to 2021. The large market share and high growth rate of this technology segment can be attributed to the ease of use associated with the technology and reduction in off-target effect of CRISPR.

Get The PDF Brochure For This Report@
http://www.marketsandmarkets.com/pdfdownload.asp?id=231037000

On the basis of applications, the global genome editing market is segmented into cell line engineering, animal genetic engineering, plant genetic engineering, and other applications (diagnostics and therapeutics). The cell line engineering segment is estimated to account for the largest share of the global genome editing market in 2016. This segment is also projected to have the highest growth rate in the forecast period.

A number of factors such as increasing funding from governments and private organizations, growing industry focus on stem cell research, and increasing global awareness about stem cell therapies through various organizations are driving the growth of the cell line engineering applications segment

On the basis of end user, the global genome editing market is segmented biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations.

Request for the Customization of this Report@
http://www.marketsandmarkets.com/requestCustomization.asp?id=231037000

The biotechnology & pharmaceutical companies segment is estimated to account for the largest share of the global genome market in 2016. This segment is also projected to have the highest growth rate in the forecast period. Factors such as the rapidly increasing aging population and the growing prevalence of infectious diseases and cancer have propelled the demand for genome editing market for biotechnology & pharmaceutical companies.

On the basis of region, the global market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, North America is poised to account for the largest share of the genome editing market market, followed by Europe and Asia-Pacific. North America is also projected to have the highest growth rate in the forecast period. Factors such as the development of gene therapy in the U.S.; increasing use of GM crops; prevalence of Alzheimer’s disease, dementia, infectious diseases, and cancer in the U.S.; growing availability of research grants and funding, and genome editing standards workshops and conferences are likely to propel the market in North America.

The prominent players in the global genome editing market were Thermo Fisher Scientific, Inc. (U.S.), Merck KGAA (Germany), and Horizon Discovery Group Plc (U.K.) in 2015. These companies are dominant in the genome editing market mainly due to their well-established presence in the field of genomics, presence in over 50 countries, high R&D investments, and strong sales and distribution force. While the other players includes, Genscript Biotech Corporation (U.S.), Sangamo Biosciences, Inc. (U.S.), Integrated DNA Technologies, Inc (U.S.), Lonza Group Ltd. (Switzerland), New England Biolabs, Inc. (U.S.), Origene Technologies, Inc. (U.S.), and Transposagen Biopharmaceuticals, Inc. (U.S.).

About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441